Mediwound Ltd
MDWD18.030USD
-0.120-0.66%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
196.09MMarket Cap
LossP/E TTM
More Details of Mediwound Ltd Company
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Mediwound Ltd Info
Ticker SymbolMDWD
Company nameMediwound Ltd
IPO dateMar 20, 2014
CEOMr. Ofer Gonen
Number of employees111
Security typeOrdinary Share
Fiscal year-endMar 20
Address42 Hayarkon Street
CityYAVNE
Stock exchangeNASDAQ Global Market Consolidated
CountryIsrael
Postal code8122745
Phone972779714100
Websitehttps://www.mediwound.com/
Ticker SymbolMDWD
IPO dateMar 20, 2014
CEOMr. Ofer Gonen
Company Executives of Mediwound Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Dr. Robert J. Snyder
Dr. Robert J. Snyder
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
By Business
By Region
No Data
Shareholding Stats
Updated: 10 hours ago
Updated: 10 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Clal Biotechnology Industries Ltd
11.55%
Investor AB
6.80%
Yelin Lapidot Provident Funds Management Ltd
6.32%
HOLD Alapkezelo Zrt
5.49%
Rosalind Advisors, Inc.
3.17%
Other
66.66%
Shareholders
Shareholders
Proportion
Clal Biotechnology Industries Ltd
11.55%
Investor AB
6.80%
Yelin Lapidot Provident Funds Management Ltd
6.32%
HOLD Alapkezelo Zrt
5.49%
Rosalind Advisors, Inc.
3.17%
Other
66.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.75%
Holding Company
11.55%
Investment Advisor/Hedge Fund
9.39%
Private Equity
6.80%
Hedge Fund
4.93%
Venture Capital
2.95%
Corporation
2.17%
Individual Investor
1.42%
Research Firm
0.37%
Other
39.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
134
5.86M
45.68%
+524.92K
2025Q2
127
6.70M
61.97%
-1.10M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
2023Q2
64
5.23M
72.67%
+954.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clal Biotechnology Industries Ltd
1.48M
11.55%
--
--
Sep 30, 2025
Investor AB
872.09K
6.8%
--
--
Jun 30, 2025
Yelin Lapidot Provident Funds Management Ltd
816.74K
6.37%
-41.26K
-4.81%
Jun 30, 2025
HOLD Alapkezelo Zrt
703.43K
5.49%
+703.43K
--
Sep 22, 2025
Rosalind Advisors, Inc.
407.06K
3.17%
-99.83K
-19.69%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
388.27K
3.03%
-45.72K
-10.54%
Jun 30, 2025
Israel Biotech Fund
378.62K
2.95%
-172.63K
-31.32%
Mar 15, 2025
T. Rowe Price Associates, Inc.
369.08K
2.88%
+214.12K
+138.19%
Jun 30, 2025
Deep Insight Limited Partnership
278.18K
2.17%
-273.07K
-49.54%
Mar 15, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Israel Innovative Technology ETF
1.45%
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ARK Israel Innovative Technology ETF
Proportion1.45%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.52%
iShares Micro-Cap ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Date
Type
Ratio
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
